Eli Lilly hits pause on Aduhelm rival donanemab as execs fret about Medicare's skeptical stance on Alzheimer's drug class

Paul Schloesser

Associate Editor

While Biogen is still fighting to save its controversial drug Aduhelm from drowning in criticism, Eli Lilly execs echoed former FDA commissioner Scott Gottlieb’s comments from last week in the pharma’s Q4 earnings call this morning concerning its amyloid-targeted Alzheimer’s drug donanemab — and how the decision by CMS to restrict reimbursements on all anti-amyloid mAbs could put this field of research in jeopardy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Eli Lilly hits pause on Aduhelm rival donanemab as execs fret about Medicare's skeptical stance on Alzheimer's drug class

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Merck KGaA’s evobrutinib disappoints in PhIII multiple sclerosis test, casting dark cloud over BTK class

J&J notebook: Highlights from a day of pipeline and strategy discussion

Will the UK’s triple-pronged approach ease pricing, regulatory and financial bottlenecks?

FDA sends letter to Novartis over 'significant' Kymriah manufacturing safety concerns

IGM Biosciences cuts 22% of workforce, axes hematologic oncology program

The next phase of decentralization in clinical trials

Eli Lil­ly hits pause on Aduhelm ri­val do­nanemab as ex­ecs fret about Medicare's skep­ti­cal stance on Alzheimer's drug class

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Mer­ck KGaA’s evo­bru­ti­nib dis­ap­points in PhI­II mul­ti­ple scle­ro­sis test, cast­ing dark cloud over BTK class

J&J note­book: High­lights from a day of pipeline and strat­e­gy dis­cus­sion

Will the UK’s triple-pronged ap­proach ease pric­ing, reg­u­la­to­ry and fi­nan­cial bot­tle­necks?

FDA sends let­ter to No­var­tis over 'sig­nif­i­can­t' Kym­ri­ah man­u­fac­tur­ing safe­ty con­cerns

IGM Bio­sciences cuts 22% of work­force, ax­es hema­to­log­ic on­col­o­gy pro­gram

The next phase of de­cen­tral­iza­tion in clin­i­cal tri­als

Eli Lilly hits pause on Aduhelm rival donanemab as execs fret about Medicare's skeptical stance on Alzheimer's drug class

Merck KGaA’s evobrutinib disappoints in PhIII multiple sclerosis test, casting dark cloud over BTK class

J&J notebook: Highlights from a day of pipeline and strategy discussion

Will the UK’s triple-pronged approach ease pricing, regulatory and financial bottlenecks?

FDA sends letter to Novartis over 'significant' Kymriah manufacturing safety concerns

IGM Biosciences cuts 22% of workforce, axes hematologic oncology program

The next phase of decentralization in clinical trials